Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Braveheart Bio to Participate in TD Cowen 46th Annual Health Care Conference
This is a paid press release. Contact the press release distributor directly with any inquiries.
Braveheart Bio to Participate in TD Cowen 46th Annual Health Care Conference
PR Newswire
Mon, February 23, 2026 at 10:00 PM GMT+9 1 min read
SAN FRANCISCO, Feb. 23, 2026 /PRNewswire/ – Braveheart Bio, a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that it will participate in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026, in Boston, where executive leadership will hold one-on-one meetings with investors.
Braveheart Bio logo (PRNewsfoto/Braveheart Bio)
About Braveheart Bio
Braveheart Bio is a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care. For more information, visit braveheart.bio.
Contact
Braveheart-bio@fgsglobal.com
Cision
View original content to download multimedia:
Terms and Privacy Policy
Privacy Dashboard
More Info